Abstract
N-3,4-dimethoxycinnamoylanthranilic acid (the active ingredient in tranilast) is an amide of anthranilic acid and 3,4-dimethoxycinnamic acid. This drug has been used in Japan and South Korea since 1982 for the treatment of bronchial asthma. Subsequent studies have shown that tranilast is effective in treating a wide range of diseases, including fibrosis, proliferative disorders, and autoimmune diseases, and exhibits promising antitumor activity. However, its clinical application is limited by low bioavailability and non-selective cellular localization. As a promising approach to overcome these drawbacks, we conjugated tranilast with the lipophilic cation triphenylphosphonium (TPP+), which enables targeted delivery of the compound to mitochondria, the main source of reactive oxygen species. We have developed an efficient method for the synthesis of two previously unknown amide derivatives of tranilast bearing a TPP+ group in the side chain linked via C-6 alkyl or dipeptide linkers. The synthesis involved amidation of tranilast with aminohexanol, mesylation of the terminal hydroxyl group, and conversion of the mesylate to a bromide or azide by reaction with LiBr or NaN3. The bromoalkyl derivative of tranilast was transformed into a TPP+ conjugate by reaction with triphenylphosphine. The azide derivative was preliminarily reduced to an amine using PPh3 and conjugated with the triphenylphosphonium salt of pentanoic acid. The structures were confirmed by 1D and 2D NMR spectroscopy. Cytotoxic activity was studied in vitro against five human cancer cell lines (MCF-7, A549, K562, MDA-MB-231, SH-SY5Y) and normal HEK293T cells. Tranilast was found to be devoid of cytotoxicity (IC50 > 100 μM), while its TPP+ derivatives demonstrated antitumor activity against all tested cell lines in the low micromolar range (IC50 = 4.58–15.66 μM).
Funding Information
  • Ministry of Science and Higher Education of the Russian Federation (FMRS-2025-0033)